News, features, and commentary about cancer-related issues ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

The research lays a foundation for the possibility that aggressive prostate cancer can probably be detected through a few drops of semen or blood in the long term. Prostate cancer is the most common ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

A new study co-led by WEHI has found a simple blood test can help identify the early-stage testicular cancer patients who are ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for la ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

Accounting for 55.6% of the total, salaries and benefits were the biggest expense at $11.16 billion, up 6.45% from 2024. Mayo ...

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post ...